TITLE

Abbreviated Clinical Study Reports with Investigational Medicinal Products for Human Use: Current Guidelines and Recommendations

AUTHOR(S)
Alfaro, Vicente; Cullell-Young, Mart�n; Tanovic, Adnan
PUB. DATE
December 2007
SOURCE
Croatian Medical Journal;2007, Vol. 48 Issue 6, p871
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
28160457

 

Related Articles

  • Obesity med guideline needs reshaping, says CV Working Party.  // PharmacoEconomics & Outcomes News;10/13/2012, Issue 664, p2 

    The article reports on the recommendation of the European Medicines Agency's (EMA) Cardiovascular (CV) Working Party for the Committee for Medicinal Products for Human Use (CHMP) to consider revising and updating the guideline for medicinal products used in weight control.

  • Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Verbruggen, Alfons; Coenen, Heinz; Deverre, Jean-Robert; Guilloteau, Denis; Langstrom, Bengt; Salvadori, Piero; Halldin, Christer // European Journal of Nuclear Medicine & Molecular Imaging;Nov2008, Vol. 35 Issue 11, p2144 

    The purpose of this guideline is to help investigators by giving an overview of relevant current EU requirements concerning the quality of starting materials and final drug products (the radiopharmaceuticals), the non-clinical safety studies and dosimetry considerations whilst designing a human...

  • First-in-man clinical trials for high risk products.  // WHO Drug Information;2007, Vol. 21 Issue 2, p130 

    The article informs that a draft guideline for first-in-man clinical trials for potential high-risk medicinal products has been adapted by the Committee for Medicinal Products for Human Use. The guideline aims to minimize the risk that occurred during the first-in-man clinical trials of TGN1412...

  • Overview of Guidelines and Recommendations for the Planning, Conduct and Reporting of Company-Sponsored Observational, Noninterventional Studies in Europe. Schnetzler, Gabriel; Hayward, Colin // Pharmaceutical Medicine - New Zealand;2011, Vol. 25 Issue 4, p235 

    Much of current clinical and public health knowledge comes from observational research and noninterventional studies (NIS). An increasing number of guidelines and recommendations have been developed to strengthen the methodology, conduct and reporting of different types of NIS. The purpose of...

  • The EMEA Guideline on First-in-Human Clinical Trials and Its Impact on Pharmaceutical Development. MILTON, MARK N.; HORVATH, CHRISTOPHER J. // Toxicologic Pathology;2009, Vol. 37 Issue 3, p363 

    The article presents the guideline for first-in-human (FIH) clinical trials issued by the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP). The guideline was established in response to a clinical trial of the TGN1412 monoclonal antibody that resulted to...

  • Review of the regulations for clinical research in herbal medicines in USA. Tang, Tony; Li, Fang-zhou; Afseth, Janyne // Chinese Journal of Integrative Medicine;Dec2014, Vol. 20 Issue 12, p883 

    In 2012, USA Food and Drug Administration (FDA) approved 39 new drugs, however, there are only two botanical drugs (one topical and one oral) approved by FDA since the publication of the FDA's industry guidelines for the botanical drug product in June 2004. The approval shows the Western...

  • EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Kapucu, Özlem; Nobili, Flavio; Varrone, Andrea; Booij, Jan; Borght, Thierry; Någren, Kjell; Darcourt, Jacques; Tatsch, Klaus; Laere, Koen // European Journal of Nuclear Medicine & Molecular Imaging;Dec2009, Vol. 36 Issue 12, p2093 

    These guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The purpose of the guidelines is to assist nuclear medicine practitioners when making recommendations, performing, interpreting, and reporting the results of brain perfusion...

  • Safety of Erythropoiesis Stimulating Agents in Patients on Dialysis: Current Issues for Nephrology Nurses. Carter, Barbara; Keen, Marcia // Nephrology Nursing Journal;May/Jun2007, Vol. 34 Issue 3, p311 

    Clinical data have repeatedly shown that the erythropoiesis stimulating agents (ESAs) Epoetin alfa and darbepoetin alfa are safe and efficacious to treat anemia in patients on dialysis when used in accordance with the product label. The safety profile of ESAs has recently been updated based on...

  • Improving access to clinical practice guidelines with an interactive graphical interface using an iconic language. Pereira, Suzanne; Hassler, Sylvain; Hamek, Saliha; Boog, César; Leroy, Nicolas; Beuscart-Zéphir, Marie-Catherine; Favre, Madeleine; Venot, Alain; Duclos, Catherine; Lamy, Jean-Baptiste // BMC Medical Informatics & Decision Making;2014, Vol. 14 Issue 1, p77 

    Background: Clinical practice guidelines are useful for physicians, and guidelines are available on the Internet from various websites such as Vidal Recos. However, these guidelines are long and difficult to read, especially during consultation. Similar difficulties have been encountered with...

  • European Launch Imminent After CHMP OK for Lixisenatide. Sheridan, Cormac // BioWorld International;11/21/2012, Vol. 17 Issue 47, p1 

    The article reports on the approval of the once-daily glucagon-like peptide 1(GLP-1) agonist Lyxumia for the treatment of type II diabetes from Zealand Pharmaceuticals A/S by the Committee for Medicinal Products for Human Use of the European Medicines Agency. The drug has been recommended for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics